ArticleLeukemia2017
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Anti-Tumor Strategies of Photothermal Therapy Combined with Other Therapies Using Nanoplatforms.Pharmaceutics · 2025Review
- T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles.Nature communications · 2023Article
- Investigating silver nanoparticles and resiquimod as a local melanoma treatment.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2023Article
- The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies.Vaccines · 2023Review
- The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.International journal of oncology · 2022Article
- Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled withJournal of medicinal chemistry · 2022Review
- Emerging role of RNA sensors in tumor microenvironment and immunotherapy.Journal of hematology & oncology · 2022Review
- Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands.BioImpacts : BI · 2022Review
- Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular CarcinomaFrontiers in oncology · 2022Article
- Toll-like receptor-targeted anti-tumor therapies: Advances and challenges.Frontiers in immunology · 2022Review
- Role of Toll-like receptors in natural killer cell function in acute lymphoblastic leukemia.Oncology letters · 2021Review
- Follicular lymphoma and macrophages: impact of approved and novel therapies.Blood advances · 2021Article
- Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.Cancers · 2021Article
- Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors.Nature communications · 2021Article
- Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC).Scientific reports · 2021Article
- Role of toll-like receptor 7 (TLR7) in voluntary alcohol consumption.Brain, behavior, and immunity · 2020Article
- Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.Journal of immunology research · 2020Review
- Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Review
- Development and Significance of Mouse Models in Lymphoma Research.Current hematologic malignancy reports · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many patients ultimately relapse and become refractory to treatment. The glycoengineered anti-CD20 mAb obinutuzumab was developed to induce enhanced antibody-dependent cellular cytotoxicity, antibody-dependent phagocytosis and direct cell death and was shown to lead to improved outcomes in a randomized study in B-CLL. We hypothesized that immune stimulation through Toll-like receptor 7 (TLR7) agonism in combination with obinutuzumab would further enhance lymphoma clearance and the generation of long-term antitumor immune responses. Here we demonstrate, in syngeneic human CD20 (hCD20)-expressing models of lymphoma, that systemic administration of a TLR7 agonist (R848) increases responses when administered in combination with obinutuzumab and protects against disease recurrence. Depletion studies demonstrate that primary antitumor activity is dependent on both NK cells and CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.